No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer

byTeddy Guo

February 17, 2021

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Positive Anti-Spike or Anti-Nucleocapsid Antibody Status is Associated with Reduced Incidence of SARS-CoV-2 Reinfection in Health Care Workers

RelatedReports

Population-based risk factors and geographical trends identified for vitiligo

Oncology

Increasing cancer incidence rates in younger and older adults worldwide

October 20, 2025

Blindness and visual impairment decreasing worldwide

AI Roundup

Punjab launches AI screening program this week

September 30, 2025

AI Roundup

2MM: AI Roundup –Lilly launches TuneLab AI drug discovery, smart wound healing bandage, and Punjab cancer screening [September 25th, 2025]

September 28, 2025

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Endocrinology

Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

August 28, 2025

Long-term use of rituximab associated with lower rates of AAV relapse

Avacopan non-inferior to prednisone in the treatment of ANCA-associated vasculitis

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Bimekizumab is tolerable and efficacious for patients with moderate to severe plaque psoriasis

Combined MRI and NIH stroke scores may predict stroke prognosis

Maternal chronic conditions increase risk of cerebral palsy among offspring

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports